Brensocatib is a prescription medicine indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. It is available as tablets for oral use. MedsAcross supplies Brensocatib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older.
Source: US FDA prescribing information
Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Activated NSPs are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation. In cell-based assays, DPP1 inhibition by brensocatib reduces the activity of NSPs including neutrophil elastase, cathepsin G, and proteinase 3.
Source: US FDA prescribing information
Recommended dosage: 10 mg or 25 mg orally once daily with or without food. Recommended Dosage The recommended dosage of BRINSUPRI is as follows: 10 mg orally once daily with or without food or 25 mg orally once daily with or without food Missed Dose(s) Patients who miss a dose should take the next dose at their regular time the next day. Do not double the dose to make up for the missed dose.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Dermatologic Adverse Reactions: Monitor for new rash or skin conditions and refer to dermatology for evaluation. Gingival and Periodontal Adverse Reactions: Gingival and periodontal adverse reactions can occur with BRINSUPRI use. Refer to the dental care services for regular dental checkups and advise patients to perform routine dental hygiene. Live Attenuated Vaccines: It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of the vaccines. Avoid use of live attenuated vaccines.
Source: US FDA prescribing information
The following adverse reactions are described elsewhere in the labeling: Dermatologic Adverse Reactions Gingival and Periodontal Adverse Reactions Most common adverse reactions (incidence ≥2%): upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, hypertension. or https://www.fda.gov/medwatch.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Store in original container.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Brensocatib, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Brinsupri 10 mg tabletOral | Insmed | US FDA | Available on request |
| Brinsupri 25 mg tabletOral | Insmed | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Brensocatib and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Brensocatib, including Brinsupri.
Yes. The US FDA first approved Brensocatib on 12 August 2025, according to Drugs@FDA.
Yes. Brensocatib has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Brensocatib is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Brensocatib is classified under ATC code R03 (Asthma and COPD medicines).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.